News

The European Parliament’s Public Health Committee has adopted a draft bill to enhance investment and manufacturing capacity for critical medicines, aiming to reduce EU dependency on external suppliers.

Read more...

The European Parliament's Public Health Committee has adopted a draft bill to boost investment in critical medicines manufacturing and diversify supply chains across the EU.

Read more...

The EMA Management Board celebrated the political agreement on groundbreaking EU pharmaceutical legislation and outlined 2026 priorities focused on implementation, innovation, and regulatory modernization.[1]

Read more...

Dr. Lu Xianping, founder and chairman of Chipscreen Biosciences, has been named the Chinese mainland winner of the EY Entrepreneur Of The Year 2025 awards for his contributions to China's pharmaceutical innovation ecosystem.

Read more...

Theriva Biologics announces positive EMA scientific advice on the Phase 3 trial design of VCN-01 combined with standard chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma treatment.[5]

Read more...

Ipsen has signed a deal worth up to $1 billion with China's Simcere to acquire rights to a preclinical antibody-drug conjugate (ADC), enhancing its oncology pipeline with manufacturing and regulatory responsibilities.

Read more...

Swedish biotech Diamyd Medical aligns with FDA to advance primary efficacy readout in its registrational Phase 3 trial for antigen-specific immunotherapy Diamyd, targeting recent-onset type 1 diabetes patients.

Read more...

South Korean biotech ABL Bio announced on December 26, 2025, that it will receive a USD 40 million upfront payment and USD 15 million equity investment from Eli Lilly for its Grabody platform license, research, and collaboration agreement.[3]

Read more...

European Parliament and Council negotiators have agreed on a provisional deal to revamp EU pharmaceutical policy, enhancing innovation, supply security, and regulatory efficiency.

Read more...

Taiwan-based Caliway Biopharmaceuticals has completed its U.S. FDA IND submission for a Phase 2 study of CBL-514 combined with tirzepatide for enhanced fat reduction and weight maintenance.

Read more...